GHRP-6 (Growth Hormone Releasing Peptide-6) Guide

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of 873.0 g/mol that stimulates growth hormone secretion by activating the ghrelin receptor (GHS-R1a). It is the first compound in the GHRP family and the ancestor of every subsequent GH secretagogue, including GHRP-2, hexarelin and ipamorelin. Two D-amino acid residues (D-Trp at position 2, D-Phe at position 5) protect it from rapid enzymatic breakdown, a design feature that Bowers built into the molecule from the outset.

GHRP-6 is distinguished from its descendants primarily by its appetite effect. Because it activates the same hypothalamic receptors that the hunger hormone ghrelin uses, GHRP-6 triggers the most intense appetite response of any injectable GH secretagogue – a feature that is either valuable or disqualifying depending on the research context. It also raises cortisol and prolactin at higher doses, unlike the more selective ipamorelin, and sits in the middle of the GHRP potency ranking behind hexarelin but ahead of its parent scaffold GHRP-6’s own precursors.

The Enkephalin Accident That Founded a Field

In the late 1970s, Cyril Bowers at Tulane University was studying chemical modifications of met-enkephalin, an endogenous opioid peptide, when he observed that certain analogs unexpectedly released growth hormone from pituitary cell cultures. By 1981, Bowers had designed GHRP-6 as a purpose-built hexapeptide optimised for GH release, and by 1984 his group had demonstrated that it specifically and dose-dependently released GH both in vitro and in vivo through a mechanism entirely separate from the known GHRH pathway (Bowers et al., Endocrinology, 1984). This was the first proof that a second, independent route to GH secretion existed at the pituitary level – a finding whose consequences would take fifteen years to fully unfold.

The receptor that GHRP-6 activated remained unidentified until 1996, when Howard and colleagues at Merck cloned GHS-R1a, a seven-transmembrane G-protein-coupled receptor concentrated in the hypothalamus and pituitary (Howard et al., Science, 1996). Three years later, Kojima and Kangawa in Japan used GHS-R1a as a molecular fishing rod to isolate its endogenous ligand from the stomach – a 28-amino-acid peptide they named ghrelin, from the Proto-Indo-European root ghre meaning “to grow” (Kojima et al., Nature, 1999). GHRP-6 had led, through reverse pharmacology, to the discovery of the body’s own hunger hormone. As Bowers himself summarised it: the unnatural peptide begot the natural one.

The bottom line: GHRP-6 is the original synthetic GH secretagogue whose existence led directly to the cloning of the ghrelin receptor in 1996 and the discovery of ghrelin in 1999.

GHRP-6 activates GHS-R1a on somatotroph cells in the anterior pituitary, triggering a phospholipase C / calcium signalling cascade that produces a rapid, dose-dependent pulse of GH. This pathway is pharmacologically distinct from the cAMP / PKA cascade used by GHRH, which is why combining a GHRP with a GHRH analogue produces synergistic GH release rather than simple addition. GHRP-6 also suppresses somatostatin tone, further amplifying the GH pulse.

Beyond the pituitary, GHRP-6 binds CD36, a class B scavenger receptor expressed in cardiac tissue, macrophages and hepatic stellate cells. This second receptor is the basis for a body of cytoprotective research entirely separate from the GH axis, discussed in the evidence section below.

The Appetite Question

GHRP-6 activates GHS-R1a in the arcuate nucleus of the hypothalamus, directly stimulating neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons – the same orexigenic circuitry that endogenous ghrelin uses to drive hunger. The appetite spike typically begins 15 to 30 minutes after administration and lasts 30 to 60 minutes. In clinical and community reports, GHRP-6 produces the most intense appetite stimulation of any injectable GH secretagogue, substantially exceeding the effect seen with GHRP-2 or hexarelin (Lawrence et al., Endocrinology). This is not a side effect that can be separated from the GH response; both effects flow from the same receptor activation.

Unlike ipamorelin, which is selective for GH release and spares cortisol and prolactin, GHRP-6 also stimulates the hypothalamic-pituitary-adrenal axis. At standard research doses, it produces transient increases in ACTH, cortisol and prolactin that return to baseline within two to three hours (Ghigo et al., Journal of Clinical Endocrinology and Metabolism). At higher or repeated doses, the cortisol and prolactin elevations can become clinically relevant.

The bottom line: GHRP-6 cannot separate its GH-releasing effect from its appetite-stimulating effect because both originate from the same ghrelin-receptor activation.

Why GHRP-6 Was Superseded

GHRP-6’s non-selective profile created the pharmacological problem that its successors were designed to solve. Each subsequent GHRP addressed a specific GHRP-6 limitation. GHRP-2 (Bowers’ own D-2-Nal optimisation) achieved higher GH output per unit dose with a slightly narrower off-target hormonal footprint, though it still raised cortisol and prolactin. Hexarelin, a Deghenghi modification from the Mediolanum programme in the 1990s, pushed GH potency further still but ran into dose-limiting desensitisation. Ipamorelin, the Raun 1998 pentapeptide, solved the selectivity problem almost entirely: it releases GH without measurable appetite stimulation, cortisol elevation or prolactin rise at standard doses.

This progression left GHRP-6 without a clear therapeutic niche in GH research. It is not the most potent (hexarelin), not the most selective (ipamorelin), not the most convenient (MK-677’s oral route), and not the only approved option (GHRP-2 has a Japanese diagnostic approval). What GHRP-6 retains is its unique position as the founding compound of the class, its strong appetite-stimulating effect (which may be specifically useful in cachectic or underweight research populations), and, through the CIGB programme, an emerging second life as a cytoprotective agent operating through CD36 rather than GHS-R1a.

GHRP-6 has been studied since the early 1980s, but its clinical development stalled after recombinant human growth hormone became commercially available, and no pharmaceutical company has taken it through a full regulatory approval pathway. The most advanced human clinical programme sits not in GH therapeutics but in cytoprotection, run by Cuba’s Center for Genetic Engineering and Biotechnology (CIGB).

Study / Programme	Evidence Tier	Key Finding
Bowers et al. 1984 (Endocrinology)	Foundational / in vivo + in vitro	First demonstration of specific, dose-dependent GH release through a non-GHRH pathway
Cabrales et al. 2013 (Eur J Pharm Sci)	Phase I PK (9 healthy males)	Distribution half-life 7.6 min; elimination half-life 2.5 h; bi-exponential clearance
Berlanga-Acosta et al. 2007 (Clin Sci)	Preclinical (porcine MI model)	Infarct mass reduced by 78%; wall thickness preserved by 50%
Berlanga-Acosta et al. 2012 (Biotecnol Apl)	Preclinical (rat liver fibrosis)	Hepatic fibrosis reduced >75%; cirrhotic nodules reduced up to 60%
Mendoza-Mari et al. 2016 (Plast Surg Int)	Preclinical (rat wound healing)	Topical GHRP-6 attenuated inflammation, reduced hypertrophic scarring via CD36 / PPARgamma
Hernandez-Bernal et al. 2024 (Front Neurol)	Phase I/II (36 acute stroke patients)	EGF + GHRP-6 combination safe; improved NIHSS, Barthel and mRS at 90 and 180 days; higher survival at 6 months
Bellone et al. 1995 (Eur J Endocrinol)	Human (paediatric, oral route)	Oral GHRP-6 retained GH-releasing activity in children with short stature

The Cuban Cytoprotection Programme

The most active clinical development of GHRP-6 has taken place at Cuba’s CIGB, led by Jorge Berlanga-Acosta and colleagues. Their work has focused not on GH release but on CD36-mediated cytoprotection – the ability of GHRP-6 to protect cells and tissues from ischaemic, fibrotic and inflammatory damage independently of growth hormone.

In preclinical models, GHRP-6 reduced infarct mass by 78% in a porcine myocardial infarction model while preserving wall thickness and suppressing oxidative stress markers (Berlanga-Acosta et al., Clinical Science, 2007). In a rat liver-fibrosis model using carbon tetrachloride, it cut fibrotic tissue accumulation by more than 75% and decreased cirrhotic nodules by up to 60%, operating through downregulation of TGF-beta1 and CTGF (Berlanga-Acosta et al., Biotecnologia Aplicada, 2012). Applied topically in a rat wound model, it attenuated inflammation and reduced hypertrophic scarring by activating PPARgamma via CD36 (Mendoza-Mari et al., Plastic Surgery International, 2016).

This preclinical programme moved into humans in a Phase I/II open-label trial combining EGF and GHRP-6 in 36 patients with acute ischaemic stroke, published in Frontiers in Neurology in 2024 (Hernandez-Bernal et al.). The combination was safe, and treated patients showed favourable neurological and functional outcomes on the NIHSS, Barthel index and modified Rankin scale at both 90 and 180 days, with a higher survival rate at six months. The trial supported progression to a Phase III study. This represents the most advanced human clinical programme for any GHRP compound worldwide.

Pharmacokinetics in Humans

The only formal pharmacokinetic study of GHRP-6 in humans was conducted by the CIGB group and published in 2013 (Cabrales et al., European Journal of Pharmaceutical Sciences). Nine healthy male volunteers received single intravenous boluses of 100, 200 or 400 micrograms per kilogram. GHRP-6 followed bi-exponential clearance with a distribution half-life of 7.6 minutes and an elimination half-life of 2.5 hours, measured by a validated LC-MS method using isotope-labelled internal standard. The lower limit of quantification was reached in all subjects at 12 hours after administration. These are substantially longer half-lives than those seen with GHRH analogues, reflecting the D-amino acid modifications that protect GHRP-6 from enzymatic degradation.

Oral Bioavailability and the Paediatric Context

One unusual property of GHRP-6, noted early in its development, is that it retains GH-releasing activity when administered orally – a feature shared with MK-677 but not with most injectable peptides. Bellone and colleagues demonstrated in 1995 (European Journal of Endocrinology) that oral GHRP-6 produced measurable GH responses in children with short stature, suggesting that the compound survives first-pass metabolism well enough to reach the pituitary at bioactive concentrations. The CIGB group subsequently described GHRP-6 as “effective when orally administered, stable, and economically low priced” in their 2017 review (Berlanga-Acosta et al., Clinical Medicine Insights: Cardiology).

This oral activity was investigated as a potential route to a paediatric GH-deficiency treatment that would avoid daily injections of recombinant GH. The idea never progressed to Phase III trials, partly because GHRP-6’s appetite and cortisol effects made it a poor candidate for chronic paediatric use, and partly because the arrival of commercially successful recombinant GH products removed the pharmaceutical incentive. Nevertheless, the oral-bioavailability data remain relevant to any future development of GHRP-6 as a cytoprotective agent, where an oral formulation could simplify delivery.

Use as a GH Provocative Test

Outside the CIGB cytoprotection programme, the most consistent clinical use of GHRP-6 has been as a provocative stimulus in GH-deficiency diagnostic protocols. A single intravenous bolus of GHRP-6 produces a rapid, reproducible GH spike whose magnitude indicates the functional capacity of pituitary somatotrophs. This is analogous to the diagnostic use of GHRP-2 (pralmorelin) in Japan, where it received regulatory approval specifically as a GH-stimulation test agent. GHRP-6 has been used in research settings for GH-deficiency evaluation in both adults and children, often combined with GHRH to increase diagnostic sensitivity (Popovic et al., European Journal of Endocrinology; Leal-Cerro et al., Clinical Endocrinology, 1998). However, GHRP-6 was never approved for this diagnostic use, and the test remains off-label wherever GHRP-6 is available.

The bottom line: GHRP-6 has extensive preclinical and early clinical evidence in cytoprotection, but its GH-related development stalled in the 1990s when recombinant human GH became the commercial standard.

GHRP-6 has never received marketing approval from any national medicines regulator and has no approved therapeutic indication anywhere in the world.

Jurisdiction	Status	Detail
US (FDA)	Not approved; not eligible for 503A compounding	Placed in former Category 3 (nominated without adequate support). Not on Category 1 list. FDA warning letters issued to United Pharmacy, ImprimisRx and Triad Rx in February-March 2019 for compounding GHRP-6 without lawful basis
UK (MHRA)	No marketing authorisation	Treated as an unlicensed medicine; supply and advertising subject to MHRA enforcement
Australia (TGA)	Schedule 4 (Prescription Only)	Growth hormone releasing peptides are listed as prescription-only medicines under the Poisons Standard. Access possible via SAS or Authorised Prescriber pathway
WADA	Prohibited at all times (S2.2.4)	Named explicitly as a GH-Releasing Peptide. Classified as a Specified Substance. Detection via LC-MS/MS in urine; biomarker signatures detectable 7-14 days

For a fuller explanation of how the FDA’s interim category system and 503A/503B pathways work, see our guide to FDA Category 1 vs Category 2. The wider legal position in each market is set out in our guides to peptide legality in the US, the UK and Australia.

The bottom line: GHRP-6 sits outside every major regulatory pathway for lawful compounding in the US, and the FDA has actively enforced against pharmacies that compounded it.

GHRP-6’s side-effect profile is dominated by three mechanism-based effects that flow directly from its ghrelin-receptor agonism and distinguish it from more selective secretagogues.

Appetite stimulation is the defining adverse event. The orexigenic drive begins within 15 to 30 minutes and can be intense enough to be mistaken for hypoglycaemia, although blood glucose measurements in studies and community reports do not show hypoglycaemic readings. The hunger diminishes somewhat after several weeks of repeated use but does not fully disappear. For cachectic or underweight populations, this effect is potentially beneficial; for others it is a significant limitation.

Cortisol and prolactin elevation occurs in a dose-dependent fashion. At lower doses, the increases are transient and within physiological range, returning to baseline within two to three hours. At higher or repeated doses, sustained cortisol stimulation raises theoretical concerns about metabolic effects, sleep disruption and immune suppression, and sustained prolactin elevation can produce symptoms including mood changes and, rarely, gynaecomastia. This off-target hormonal profile is the primary reason that ipamorelin, which spares both cortisol and prolactin, is generally considered the cleaner compound for pure GH research.

Fluid retention and paraesthesia are GH-class effects seen across secretagogues and exogenous GH alike. Mild bloating, joint puffiness and tingling in the hands (mimicking carpal tunnel symptoms) are reported at standard research doses and are generally reversible on cessation.

Long-term safety data in humans are essentially absent. No controlled trial has studied GHRP-6 use beyond the 14-day EGF-combination stroke protocol. The Cabrales 2013 PK study found no drug interaction with the beta-blocker metoprolol, but this is the extent of formal interaction data.

The bottom line: GHRP-6’s appetite, cortisol and prolactin effects are mechanism-based and inseparable from its GH activity, and the absence of long-term safety data remains a fundamental gap.

GHRP-6 sits within a family of compounds that share the ghrelin-receptor pathway but differ in selectivity, potency and route. The key relatives are covered in their own guides:

• GHRP-2 (pralmorelin) – Bowers’ optimised successor, more potent per unit dose, with a similar but slightly milder appetite and cortisol profile. The only GH secretagogue ever approved by a national regulator (Japan, 2004, as a diagnostic).
• Hexarelin – The most potent classical GHRP, a Deghenghi modification of the GHRP-6 scaffold with additional cardiac CD36 activity but documented desensitisation over 16 weeks.
• Ipamorelin – The selective pentapeptide that spares cortisol and prolactin. For a head-to-head with MK-677, see the ipamorelin vs MK-677 comparison.
• MK-677 (ibutamoren) – A non-peptide oral ghrelin-receptor agonist with a 24-hour half-life. Not a peptide despite frequent mislabelling.
• CJC-1295 and sermorelin act through the GHRH receptor, a separate pathway that is synergistic with GHRP signalling.

For the class-level overview of how GHRH analogues, ghrelin mimetics and GH-releasing peptides compare, see the growth hormone secretagogues hub. Any peptide purchased for research should be verified against a third-party certificate of analysis – our guide to reading a COA explains what to look for.

What is the relationship between GHRP-6 and ghrelin?

GHRP-6 is a synthetic ghrelin-receptor agonist that existed before ghrelin itself was identified. The receptor GHRP-6 activates was cloned in 1996 by Howard et al., and then used by Kojima and Kangawa to isolate ghrelin from the stomach in 1999. This sequence – synthetic ligand first, natural hormone second – is a textbook example of reverse pharmacology. GHRP-6 mimics ghrelin’s effects on GH release and appetite, but it is not identical to ghrelin in structure (six amino acids versus ghrelin’s twenty-eight) or in its full receptor-binding profile.

Why does GHRP-6 cause more hunger than other secretagogues?

GHRP-6 activates GHS-R1a in the hypothalamic arcuate nucleus more strongly than GHRP-2 or hexarelin, directly stimulating the NPY and AgRP neurons that drive orexigenic signalling. Ipamorelin, by contrast, was specifically designed to avoid hypothalamic appetite circuits while still releasing GH at the pituitary. GHRP-6 cannot be dosed to produce GH release without some degree of appetite stimulation, because both responses originate from the same receptor activation event.

Can GHRP-6 be legally compounded in the US?

No. GHRP-6 does not have a USP monograph, is not a component of any FDA-approved drug, and does not appear on the 503A bulks list. It was placed in the former Category 3 (nominated without adequate support) and has never been moved to Category 1. The FDA issued warning letters to three pharmacies in 2019 specifically for compounding drug products with GHRP-6. This is a distinctly worse regulatory position than compounds such as gonadorelin or sermorelin, which either have prior FDA approvals or sit on the Category 1 list.

How does GHRP-6 compare with GHRP-2 in potency?

GHRP-2 releases more GH per unit dose than GHRP-6 and produces a somewhat milder appetite spike, though it still elevates cortisol and prolactin. In the GHRP potency hierarchy, hexarelin sits at the top, followed by GHRP-2, then GHRP-6. GHRP-6’s advantage, if it can be called one, is that its appetite effect may be desirable in cachectic or underweight research contexts where caloric intake needs to increase alongside GH output.

What is the CIGB stroke trial?

Cuba’s Center for Genetic Engineering and Biotechnology ran a Phase I/II open-label trial (RPCEC00000214) combining EGF and GHRP-6 intravenously in 36 patients with acute ischaemic stroke, published in Frontiers in Neurology in 2024. The combination was safe and showed functional benefit at three and six months on the NIHSS, Barthel index and modified Rankin scale, with a higher six-month survival rate in the treatment groups. This trial leverages GHRP-6’s CD36-mediated cytoprotective properties rather than its GH-releasing activity and supports a Phase III study.

Is GHRP-6 detectable in anti-doping tests?

Yes. GHRP-6 is prohibited under WADA category S2.2.4 as a named GH-Releasing Peptide and is classified as a Specified Substance. Detection is by LC-MS/MS in urine, and while the parent peptide clears plasma relatively quickly (elimination half-life 2.5 hours per the Cabrales PK study), downstream biomarker signatures including altered GH pulsatility and elevated IGF-1 may remain detectable for 7 to 14 days.

Why was GHRP-6 never approved as a drug?

Several factors converged. Recombinant human growth hormone became commercially available and offered a direct, dose-controllable alternative that pharmaceutical companies preferred. GHRP-6’s non-selective profile – including the appetite, cortisol and prolactin effects – made it less attractive than newer secretagogues as a GH therapeutic. And the patent landscape around a simple hexapeptide offered limited commercial exclusivity. The result is a compound with a forty-year research history but no pharmaceutical sponsor willing to fund the Phase III trials needed for regulatory approval.